MK-2866 (Ostarine) vs YK-11
A side-by-side research comparison of MK-2866 (Ostarine) and YK-11 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MK-2866 (Ostarine) | YK-11 |
|---|---|---|
| Full name | Ostarine / Enobosarm (MK-2866) | YK-11 (Myostatin Inhibitor / SARM) |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational (not approved; banned in sport) | Research compound |
| Mechanism | Selectively binds androgen receptors in muscle and bone tissue, stimulating anabolic (muscle-building) signaling while having relatively less effect on the prostate and other androgen-sensitive tissues than testosterone. | Partial androgen receptor agonist that induces follistatin expression, creating dual myostatin inhibition and AR activation. |
| Molecular weight | 389.33 Da | 430.54 Da |
| Half-life | ~24 hours | ~6-10 hours |
| Bioavailability | Oral | ~70% oral |
| Typical dose | Commonly cited 10-25 mg/day (research) | 5-10 mg |
| Frequency | Once daily | Once daily |
| Route | Oral | Oral |
MK-2866 (Ostarine) reported benefits
- Lean muscle preservation/gain
- Bone density support (research)
- Less androgenic than steroids
- Studied for muscle wasting
YK-11 reported benefits
- Dual anabolic mechanism
- Follistatin induction
- Oral convenience
- Muscle hardening
Related comparisons
Research and educational reference only. Not medical advice.